Spravato, a depression treatment derived from club drug ketamine, was looking like a dud. Its recent success now shows a path forward for psychedelic-based medicines.
Related Posts
Streamers Can’t Get Enough of True Story TV. Cue the Lawsuits.
Litigation challenging popular shows like “Baby Reindeer” is making it more expensive to produce content for companies like Netflix.
China Auto Sales Sustain Momentum on Subsidies, Campaigns
The Chinese auto market extended its strong momentum, helped by the government’s trade-in policy.
Reckitt to Sell Some Brands, Review Infant Formula Unit in Shake-Up
Reckitt Benckiser said it would sell off some of its home-care brands and launch a strategic review of its troubled infant-formula unit Mead Johnson as […]